92 completed, 3 terminated, 3 unknown, 2 recruiting. 101 Phase 2, 8 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 101 | Completed 92, Terminated 3, Unknown 3, Recruiting 2, Active not recruiting 1 |
| Phase 3 | 8 | Completed 5, Recruiting 1, Terminated 1, Unknown 1 |
| Phase 1 | 6 | Completed 5, Unknown 1 |
Follow Neisseriaceae Infections: new trials by email Literature Review of Neisseriaceae Infections trials Research Report on Neisseriaceae Infections
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old EG-MCV4, Menveo - Meningococcal Infections | Phase 2 / Phase 3 | Recruiting | EyeGene Inc. | 1123 | 2025-10-15 | 2025-12-01 |
| Azithromycin for Meningococcal Carriage Azithromycin - Meningococcal Infections | Phase 2 | Completed | Emory University | 764 | 2024-11-12 | 2026-06-05 |
| A Study of the ACYW135 Meningococcal Polysaccharide Conjugate Vaccine ACYW135 Meningococcal Polysaccharide Conjugate Vaccine, ACYW135 Meningococcal Polysaccharide Vaccine - Meningococcal Meningitis | Phase 2 | Unknown | Aimei Vacin BioPharm (Zhejiang) Co., Ltd. | 1200 | 2024-03-20 | 2024-03-29 |
| Meningococcal B Vaccine in Patients with Asplenia Bexsero - Splenectomy; Status | Phase 2 | Recruiting | Medical University of Vienna | 80 | 2024-03-12 | 2024-11-22 |
| Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs Menstrual Cup - Bacterial Vaginosis, Vaginal Microbiome | Phase 2 | Completed | Rush University Medical Center | 408 | 2023-02-13 | 2026-08-24 |
| Antibacterial Mouthwash for Pharyngeal Gonorrhea Prevention Listerine Antiseptic Mouthwash Product, Biotene Mouthwash - Gonorrhea | Phase 2 | Completed | University of California, Los Angeles | 89 | 2022-02-17 | 2026-07-09 |
| A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Infants MenACWY-7B low dose vaccine, MenACWY-7B high dose vaccine, MenABCWY-1Gen vaccine - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 726 | 2021-11-29 | 2026-06-26 |
| Safety, Tolerability, and Immunogenicity of MenABCWY Administered on Different Dosing Schedules in Healthy Adolescents MenABCWY vaccine, Placebo - Meningitis, Meningococcal | Phase 2 | Active not recruiting | GlaxoSmithKline | 305 | 2021-11-18 | 2026-09-28 |
| Mucosal Immunity Against Neisseria Gonorrhoeae After 4CMenB Vaccination Meningococcal Group B Vaccine, Placebo - Gonorrhoea | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 52 | 2021-11-01 | 2026-10-21 |
| Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection Ceftriaxone 1000mg + doxycycline 100 mg, Cefixime 800mg + doxycycline 100 mg - Neisseria Gonorrhoeae Infection, Chlamydia Trachomatis Infection | Phase 2 | Completed | Haiphong University of Medicine and Pharmacy | 125 | 2021-07-15 | 2022-03-17 |
| A Study on the Safety, Effectiveness and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy Adolescents and Adults MenABCWY-2Gen low dose vaccine, MenABCWY-2Gen high dose vaccine, Placebo - Infections, Meningococcal | Phase 1 / Phase 2 | Completed | GlaxoSmithKline | 1440 | 2021-06-14 | 2025-05-31 |
| Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal Infection Meningococcal Group B Vaccine, Placebo - Gonococcal Infection | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2606 | 2020-12-29 | 2026-07-24 |
| Aztreonam for Pharyngeal Gonorrhea Aztreonam - Gonorrhea of Pharynx, Gonorrhea | Phase 2 / Phase 3 | Completed | University of Washington | 32 | 2019-04-05 | 2022-01-18 |
| Immunogenicity and Safety of Meningococcal ACYW135 Polysaccharide Conjugate Vaccine in Volunteers Aged From 3 to 35 Months Meningococcal ACYW135 Polysaccharide Conjugate Vaccine - Meningitis, Meningococcal | Phase 2 | Completed | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | 720 | 2018-12-21 | 2022-02-25 |
| Conjugate Vaccine Against Meningococcus C a Brazilian Project MenCC-BIO Vaccine, Combined - CRM197 - Serogroup C Meningococcal Meningitis | Phase 2 / Phase 3 | Unknown | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 1644 | 2018-09-25 | 2018-10-10 |
| Gent for Pharyngeal Gonorrhea (GC) gentamicin 360mg IM - Pharyngeal Gonococcal Infection | Phase 2 / Phase 3 | Terminated | University of Washington | 13 | 2018-09-17 | 2020-08-10 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adults 18 to 40 Years of Age MenACWY liquid vaccine with approximately 30% MenA FS (GSK3536820A), Licensed GSK MenACWY vaccine (Menveo) - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 996 | 2018-09-07 | 2021-02-09 |
| A Study to Investigate the Safety and Immunogenicity of Different Formulations of GSK Biologicals' Meningococcal ACWY Conjugate Vaccine (GSK3536820A and Menveo) Administered to Healthy Adolescents and Young Adults 10 to 40 Years of Age MenACWY liquid, MenACWY - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1707 | 2018-08-30 | 2021-02-17 |
| Study to Assess Potential Immune Interference When GlaxoSmithKline (GSK) Biologicals' MenABCWY Vaccine is Administered to Healthy Subjects Aged 10-25 Years MenABCWY vaccine, rMenB+OMV NZ (Bexsero) vaccine, MenACWY (Menveo) vaccine - Meningitis, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 520 | 2018-07-09 | 2020-02-12 |
| Online HIV Prevention for Young Male Couples 2GETHER, Existing Public Health Practice - Hiv, Chlamydia | Phase 2 | Completed | Northwestern University | 400 | 2018-04-05 | 2023-07-28 |
Showing 20 of 101. Sign in to see all of them.
Meningococcal Infections (71) · Meningitis, Meningococcal (35) · Meningitis (30) · Gonorrhea (13) · Chlamydia Infections (4) · Acquired Immunodeficiency Syndrome (2) · HIV Infections (2) · Sexually Transmitted Diseases (2) · Syphilis (2) · Bacterial Infections (1) · Central Nervous System Infections (1) · Diphtheria (1) · Gram-Negative Bacterial Infections (1) · Haemophilus Infections (1) · Infections (1)
Bacterial Infections and Mycoses (101) · Bacterial Infections (100) · Gram-Negative Bacterial Infections (100) · Infections (100) · Nervous System Diseases (48) · Neuroinflammatory Diseases (48) · Central Nervous System Bacterial Infections (35) · Central Nervous System Diseases (35) · Meningitis, Bacterial (35) · Central Nervous System Infections (34) · Meningitis (18) · Meningococcal Infections (17) · Communicable Diseases (13) · Genital Diseases (13)
Meningococcal Vaccines (32) · 4CMenB vaccine (13) · Vaccines (9) · Heptavalent Pneumococcal Conjugate Vaccine (6) · Saline Solution (4) · Tetanus Toxoid (4) · tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine (4) · MenACWY (3) · MenACWY-CRM vaccine (3) · Rubella Vaccine (3) · diphtheria-tetanus-five component acellular pertussis-inactivated poliomyelitis -Haemophilus influenzae type b conjugate vaccine (3) · Blood Specimen Collection (2) · Ceftriaxone (2) · Haemophilus influenzae type b-polysaccharide vaccine-diphtheria toxoid conjugate (2) · Measles-Mumps-Rubella Vaccine (2)
GlaxoSmithKline (29) · Novartis Vaccines (21) · Sanofi Pasteur, a Sanofi Company (16) · Pfizer (4) · National Institute of Allergy and Infectious Diseases (NIAID) (3) · Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd (2) · Northwestern University (2) · Sanofi (2) · University of Washington (2) · Wyeth is now a wholly owned subsidiary of Pfizer (2) · Aimei Vacin BioPharm (Zhejiang) Co., Ltd. (1) · Armauer Hansen Research Institute, Ethiopia (1) · Centers for Disease Control and Prevention (1) · Emory University (1) · EyeGene Inc. (1)
United States (43) · United Kingdom (15) · Finland (9) · Poland (9) · Belgium (6) · Chile (6) · Germany (6) · Italy (6) · Spain (6) · Australia (4) · Canada (4) · Czechia (4) · Austria (3) · Brazil (3) · China (3)
Jim Carey, MPH (2) · Michael E Newcomb, Ph.D. (2) · Ricky Hill, Ph.D. (2) · Abraham Aseffa Aseffa, M.D, PhD (1) · Ahmed Bedru Omer, M.D,Pediatrician (1) · Alberto Yataco, MD (1) · Elizabeth Miller, MD (1) · Francisco Diaz-Mitoma, Dr. (1)
PMID 35257644, PMID 33020485, PMID 35164991, PMID 17287313, PMID 21177912, PMID 30061029, PMID 36369456, PMID 37351709, PMID 16203934, PMID 16417952, PMID 17065257, PMID 17072120, PMID 17548138, PMID 20844462, PMID 22260988, PMID 22318278, PMID 22394992, PMID 22569484, PMID 23114372, PMID 23352429, PMID 23510357, PMID 23566945, PMID 23958808, PMID 24062178, PMID 24567843, PMID 25077420, PMID 25424810, PMID 25802309, PMID 25969894, PMID 26075813, PMID 26135245, PMID 26237742, PMID 26437712, PMID 26756390, PMID 27642132, PMID 27745812, PMID 29617982, PMID 29778515, PMID 30249694, PMID 30403954, PMID 31110098, PMID 31712813, PMID 32012111, PMID 32209248, PMID 32233959, PMID 32233961, PMID 32681472, PMID 33077658, PMID 34077644, PMID 34787449
2017 (3), 2008 (2), 2009 (2), 2014 (2), 2016 (2), 2023 (1), 5UM1AI148576-05 (1), K23AI113185 (1), R01AI170564 (1), R01MH092226 (1), R21AI147969 (1)